Stryker management to meet with Morgan Stanley » 04:5502/2502/25/20
Meeting to be held in New…
Story temporarily locked.
IntriCon reports Q4 EPS 8c, consensus (4c) » 16:4102/2402/24/20
Reports Q4 revenue…
Reports Q4 revenue $27.7MM, consensus $26.29M. "In 2019, our team committed to continuing to meet the volume demands of our key customers and partners, while pursuing new business opportunities that could best leverage our core competencies to accelerate future growth and diversify our revenue base. We made meaningful progress throughout the year that ultimately has enabled us to enter 2020. We continue to see meaningful revenue contribution from our long-standing relationship with our largest customer Medtronic (MDT) despite the stern competitive pressures they are facing domestically. We are also especially encouraged by opportunities we have identified to expand our medical business into other market segments that can significantly leverage our microelectronics, medical coil and specialty molding expertise. Similarly, we have identified new potential partnerships that we believe will position us as a leading supplier in the much-anticipated emergence of over-the-counter hearing aid sales. In order to concentrate our resources on this opportunity, we have decided to pivot our direct-to-end-consumer initiatives through Hearing Help Express entirely towards supporting product development in order to best capture the near-term benefits we see through an indirect-to-end consumer approach" said Mark Gorder, CEO of IntriCon.
Avanos announces FDA clearance of 80-Watt COOLIEF RF system » 16:1102/2402/24/20
Avanos Medical announced…
Avanos Medical announced the U.S. FDA has cleared for marketing its new, 80-Watt COOLIEF Radiofrequency system for neurological lesion procedures. This easy-to-use system, comprised of a newly designed RF generator, peristaltic pump and therapy cables, enables physicians to perform a full spectrum of procedures including Cooled, Standard, Pulsed, TransDiscal and dual Bipolar RF.
Fly Insider: Tesla, Netflix among weeks notable insider trades » 13:0202/2402/24/20
TSLA, BG, MRNA, MDT, CALX, YETI, TPX, NFLX, CDAY, IQV
Welcome to "Fly Insider,"…
Medtronic hires Sally Saba as Chief Inclusion and Diversity Officer » 10:0302/2402/24/20
Medtronic announced that…
Medtronic announced that it is hiring its first Chief Inclusion and Diversity Officer, "underscoring its continued focus and significant investment in inclusion and diversity as a business priority." Sally Saba, M.D., will assume the newly created position effective March 2. Saba will report to Carol Surface, Chief Human Resources Officer. Most recently, Saba was the Vice President of Equity, Inclusion, and Diversity at Kaiser Permanente Health Plan and Hospitals.
Medtronic says 'positive data on many innovations' presented at ATTD » 09:1702/2402/24/20
Medtronic announced "a successful conclusion" to the 13th International Conference on Advanced Technologies & Treatments for Diabetes, or ATTD 2020, which took place in Madrid, Spain, from February 19-22. The Diabetes Group at Medtronic presented a range of scientific data focusing on the company's advanced hybrid closed loop system which is currently in pivotal trials and aims to improve patient experience and outcomes; Latest extended wear infusion set technology, which is designed to last at least twice as long as current infusion sets while providing comfort of wear; MiniMed(TM) 670G system real-world data in Europe, which showed the hybrid closed loop system is delivering improved glycemic control across all glucose ranges in clinical and real-world settings; and professional CGM, with cost-effectiveness data showing the potential of the device's economic value in people with type 2 diabetes. Dr. Robert Vigersky, chief medical officer, Global Medical and Clinical Affairs for Diabetes Group at Medtronic, said: "These data underscore our commitment to continually creating new technologies that improve time in range and mean sensor glucose, reduce highs and lows, and just as importantly reduce the work of living with diabetes."
Axonics well positioned to take share from Medtronic, says Piper Sandler » 05:0002/2402/24/20
After traveling with…
After traveling with management, Piper Sandler analyst Adam Maeder continues to believe Axonics Modulation Technologies (AXNX) is well positioned to take meaningful share from Medtronic (MDT) in the sacral neuromodulation market. The market as "ripe for a growth acceleration" behind innovation, competition, and improving therapy awareness with "plenty of room" for both competitors to succeed, Maeder tells investors in a research note. He believes the opportunity for market expansion remains an "important, underappreciated" part of the Axonics story and that the company has the potential to become one of the fastest growth names in medical technology. The analyst reiterates an Overweight rating on the shares with a $44 price target.
Stryker management to meet with Morgan Stanley » 09:1502/2102/21/20
Meeting to be held in New…
Meeting to be held in New York on February 25 hosted by Morgan Stanley.
Medtronic has multi-billion opportunity not in Street estimates, says JPMorgan » 09:0502/2002/20/20
With the upcoming release…
With the upcoming release of data from Medtronic's HTN-OFF MED pivotal study on March 29, its U.S. renal denervation opportunity is "poised to make a significant comeback" following the failed HNT-3 pivotal trial in 2014, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst expects the readout to be positive, opening the door to an entirely new therapy for hypertensive patients and a multi-billion dollar "unpenetrated" global market opportunity. With a growing hypertensive population of nearly half of adults worldwide, over 40% of patients on medication still left uncontrolled, and the potential for future applications in treating other conditions, the renal denervation opportunity "represents a large and often underappreciated opportunity," says Marcus. He believes the opportunity is almost entirely left out of Medtronic's Street numbers and keeps an Overweight rating on the shares with a $128 price target.
Integer sees FY20 adj. EPS $5.10-$5.30, consensus $5.00 » 08:4102/2002/20/20
Sees revenue $1.29B-$1.31B, consensus $1.29B.